These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27216065)

  • 1. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
    Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
    Grosset J; Truffot-Pernot C; Lacroix C; Ji B
    Antimicrob Agents Chemother; 1992 Mar; 36(3):548-51. PubMed ID: 1622164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
    Lanoix JP; Betoudji F; Nuermberger E
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
    Liu Y; Pertinez H; Davies GR; Gillespie SH; Coates AR; Hu Y
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
    Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
    Park JS; Lee JY; Lee YJ; Kim SJ; Cho YJ; Yoon HI; Lee CT; Song J; Lee JH
    Antimicrob Agents Chemother; 2016 Jan; 60(1):92-8. PubMed ID: 26459901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].
    Grosset J; Truffot C; Fermanian J; Lecoeur H
    Pathol Biol (Paris); 1982 Jun; 30(6):444-8. PubMed ID: 6810288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
    Byrne ST; Denkin SM; Gu P; Nuermberger E; Zhang Y
    J Med Microbiol; 2007 Aug; 56(Pt 8):1047-1051. PubMed ID: 17644711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
    Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
    Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity?
    Pullan ST; Allnutt JC; Devine R; Hatch KA; Jeeves RE; Hendon-Dunn CL; Marsh PD; Bacon J
    BMC Infect Dis; 2016 May; 16():205. PubMed ID: 27184366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
    Liu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Harrison T; Davies G; Coates A; Hu Y
    J Antimicrob Chemother; 2018 Mar; 73(3):724-731. PubMed ID: 29244108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
    Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
    Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of katG Ser315 substitution and rpoB mutations in isoniazid-resistant Mycobacterium tuberculosis isolates from Brazil.
    Höfling CC; Pavan EM; Giampaglia CM; Ferrazoli L; Aily DC; de Albuquerque DM; Ramos MC
    Int J Tuberc Lung Dis; 2005 Jan; 9(1):87-93. PubMed ID: 15675556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.
    Lecoeur HF; Truffot-Pernot C; Grosset JH
    Am Rev Respir Dis; 1989 Nov; 140(5):1189-93. PubMed ID: 2817579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of pulmonary tuberculosis in patients with discordant phenotypic isoniazid resistance testing.
    Kim S; Lee H; Park HY; Jeon K; Huh HJ; Lee NY; Jeong BH
    Respir Med; 2017 Dec; 133():6-11. PubMed ID: 29173450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of isoniazid-resistant pulmonary tuberculosis.
    Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Lim SY; Lim SY; Koh WJ
    BMC Infect Dis; 2008 Jan; 8():6. PubMed ID: 18211720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower cytotoxicity, high stability, and long-term antibacterial activity of a poly(methacrylic acid)/isoniazid/rifampin nanogel against multidrug-resistant intestinal Mycobacterium tuberculosis.
    Chen T; Li Q; Guo L; Yu L; Li Z; Guo H; Li H; Zhao M; Chen L; Chen X; Zhong Q; Zhou L; Wu T
    Mater Sci Eng C Mater Biol Appl; 2016 Jan; 58():659-65. PubMed ID: 26478357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.